Abstract
Derivatives of dimethy-2-phenoxyethylsulfonium p-toluenesulfonate (1) were evaluated for anti-allergic activity to develop the drug for treatment of type I allergic diseases as a lead optimization step. The IgE-induced passive cutaneous anaphylaxis (PCA) of rats was inhibited upon oral administration by 3-ethoxy, 3-phenoxy, and 2, 3-diethoxypropoxyphenoxy derivatives. The lead compound 2-[4-(3-ethoxy-2-hydroxypropoxy)phenoxy]ethyldimethyl- sulfonium p-toluenesulfonate (11) was selected as a candidate for preclinical study by considering its toxicity and cholinergic activity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
